Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

PSDSS (Prostate Cancer-Specific Survival)

The Peritoneal Surface Disease Severity Score (PSDSS) is a specific prognostic tool for patients with colorectal peritoneal metastases being considered for Cytoreductive Surgery (CRS) and HIPEC.

Evidence-based context for fast calculator use

Purpose:
PSDSS stratifies survival in colorectal peritoneal metastases using symptoms, PCI, and histology to assess cytoreductive surgery candidacy.
Population:
patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model
Factors:
Clinical Symptoms, Peritoneal Cancer Index, Primary Tumor Histology, Primary Lymph Node Status
Reference:
Pelz JO, Stojadinovic A, Nissan A, et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9-15.
HomePSDSS (Prostate Cancer-Specific Survival)
Pin your most used calculators here by clicking the star in the dropdown.

PSDSS (Prostate Cancer-Specific Survival)

Clinical Context & Background

The Peritoneal Surface Disease Severity Score (PSDSS) is a specific prognostic tool for patients with colorectal peritoneal metastases being considered for Cytoreductive Surgery (CRS) and HIPEC. It combines clinical symptoms, tumor burden (PCI), histology, and nodal status to stratify survival.
Primary Source EvidencePelz JO, Stojadinovic A, Nissan A, et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9-15.
Formula Logic
Sum of weighted points for Symptoms, PCI, Histology, and N-Stage.

Reference Data

StageTotal ScoreMedian Survival (Historical)
Stage I2 - 386 months
Stage II4 - 743 months
Stage III8 - 1029 months
Stage IV> 1019 months (Poor candidates)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use PSDSS (Prostate Cancer-Specific Survival) when pSDSS stratifies survival in colorectal peritoneal metastases using symptoms, PCI, and histology to assess cytoreductive surgery candidacy.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Stage I through Stage IV.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary site, histology, stage, surgery status, systemic-treatment timing, and disease-specific guideline before applying the result.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer thresholds across colorectal, GIST, gastric, appendiceal, and other peritoneal malignancies.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model

How to apply this result

For a representative case, verify Clinical Symptoms, Peritoneal Cancer Index, Primary Tumor Histology, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

GI, GIST & Peritoneal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Modified Glasgow Prognostic Score (mGPS)Fong Clinical Risk Score (CRS)Peritoneal Carcinomatosis Index (PCI)

Frequently Asked Questions

When should PSDSS (Prostate Cancer-Specific Survival) be used?

Use it for patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model when all required inputs and the intended clinical setting are confirmed.

Can PSDSS (Prostate Cancer-Specific Survival) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.